R2 Technology has had a corner on the FDA-approved computer-aided detection (CAD) technology market, but CADx Medical Systems is ready to jump in.CADx submitted the premarket approval application for its Second Look CAD technology in three parts. The
R2 Technology has had a corner on the FDA-approved computer-aided detection (CAD) technology market, but CADx Medical Systems is ready to jump in.
CADx submitted the premarket approval application for its Second Look CAD technology in three parts. The first component has already been approved. The second and third modules are slated to receive approval by the end of the year, according to CADx. n
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.